65,437 trials
Asthma
Primary: Number of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an AI Device at Home — 113; 112; 108 Participants
Chronic Phase Chronic Myeloid Leukemia
Primary: Major Molecular Response (MMR) Rate — 47.6 Percentage of Participants
Hypertension
Primary: Area Under the Concentration-time Curve — 690.43; 820.86; 86.442; 114.55 ng*hr/mL
Healthy
Primary: Mean Plasma Concentration (AUC) of Cyclobenzaprine — 47,074.19; 94,874.26; 50,263.16 pg.hr/mL
Rheumatoid Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 4; 4; 6 participants
Generalized Aggressive Periodontitis · Aggressive Periodontitis
Primary: The Primary Outcome Variable Was Probing Depth. — 4.57; 4.18; 3.12; 2.91 mm — p=<0.01
Stage IA Skin Melanoma · Stage IB Skin Melanoma · Stage IIA Skin Melanoma
Primary: Level of Activated STAT1(Phospho-STAT1) — 5.96; 4.80 MU/m2 — p=.22
Alzheimer's Disease (AD)
Primary: Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan Outcomes — 137 Participants
Coronary Artery Disease
Primary: Safety - Frequency of Major Adverse Cardiac Events (MACE) Within 30 Days of the Procedure. — 57 events
Respiratory Muscle Weakness
Primary: Weaning Time From Mechanical Ventilation — 5; 5 hours — p=0.84
Thyroid Cancer
Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants
Impaired Glucose Tolerance
Primary: Number of Participants Who Experience at Least One Adverse Events — 88 Participants
Endstage Renal Disease
Primary: Number of Diagnostic Ultrasound Exams — 142 Participants
Shoulder Arthroscopy
Primary: Number of Patients With Paradoxical Diaphragmatic Movement — 16; 8 Participants
Obstructive Sleep Apnoea
Primary: 4% Oxygen Desaturation Index (ODI, 4%) — 26.9; 19.5 oxygen desaturation events/hour